Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2401860
Max Phase: Preclinical
Molecular Formula: C26H21F6N3O2S
Molecular Weight: 553.53
Molecule Type: Small molecule
Associated Items:
ID: ALA2401860
Max Phase: Preclinical
Molecular Formula: C26H21F6N3O2S
Molecular Weight: 553.53
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(C)(C)c1ccccc1Oc1ncccc1Nc1nc(C(F)(F)F)c(-c2ccc(OC(F)(F)F)cc2)s1
Standard InChI: InChI=1S/C26H21F6N3O2S/c1-24(2,3)17-7-4-5-9-19(17)36-22-18(8-6-14-33-22)34-23-35-21(25(27,28)29)20(38-23)15-10-12-16(13-11-15)37-26(30,31)32/h4-14H,1-3H3,(H,34,35)
Standard InChI Key: PJQAVAOCYJGQHU-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 553.53 | Molecular Weight (Monoisotopic): 553.1259 | AlogP: 8.96 | #Rotatable Bonds: 6 |
Polar Surface Area: 56.27 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
#RO5 Violations: 2 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 10.05 | CX Basic pKa: 2.22 | CX LogP: 9.52 | CX LogD: 9.52 |
Aromatic Rings: 4 | Heavy Atoms: 38 | QED Weighted: 0.24 | Np Likeness Score: -1.37 |
1. Pi Z, Sutton J, Lloyd J, Hua J, Price L, Wu Q, Chang M, Zheng J, Rehfuss R, Huang CS, Wexler RR, Lam PY.. (2013) 2-Aminothiazole based P2Y(1) antagonists as novel antiplatelet agents., 23 (14): [PMID:23743287] [10.1016/j.bmcl.2013.05.025] |
2. Hossain N, Ivanova S, Timén ÅS, Bergare J, Mussie T, Bergström L.. (2013) Design, synthesis and structure-activity relationships of zwitterionic spirocyclic compounds as potent CCR1 antagonists., 23 (14): [PMID:23769642] [10.1016/j.bmcl.2013.05.087] |
Source(1):